Csaba P Kovesdy
Overview
Explore the profile of Csaba P Kovesdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
594
Citations
18862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Narasaki Y, Kovesdy C, You A, Sumida K, Mallisetty Y, Surbhi S, et al.
Lancet Reg Health Am
. 2024 Jul;
36:100814.
PMID: 38993538
Background: We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and...
12.
Mazumder H, Haque Mondol M, Rahman M, Khan R, Doza S, Unicomb L, et al.
Kidney Int Rep
. 2024 Jun;
9(6):1860-1875.
PMID: 38899224
Introduction: Men are vulnerable to ambient heat-related kidney disease burden; however, limited evidence exists on how vulnerable women are when exposed to high ambient heat. We evaluated the sex-specific association...
13.
Makhammajanov Z, Kabayeva A, Auganova D, Tarlykov P, Bukasov R, Turebekov D, et al.
Sci Rep
. 2024 Jun;
14(1):14014.
PMID: 38890379
Proteinuria poses a substantial risk for the progression of chronic kidney disease (CKD) and its related complications. Kidneys excrete hundreds of individual proteins, some with a potential impact on CKD...
14.
Sumida K, Shrestha P, Mallisetty Y, Thomas F, Gyamlani G, Streja E, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e246822.
PMID: 38625700
Importance: Inflammatory bowel disease (IBD) is associated with adverse clinical outcomes, including chronic kidney disease and mortality, due in part to chronic inflammation. Little is known about the effects of...
15.
Sumida K, Shrestha P, Mallisetty Y, Surbhi S, Thomas F, Streja E, et al.
Mayo Clin Proc
. 2024 Apr;
99(6):913-926.
PMID: 38573302
Objective: To investigate the association of incident use of diuretics with subsequent risk of incident bone fractures. Patients And Methods: In a nationwide cohort of 863,339 US veterans receiving care...
16.
Amin S, Wall B, Thomas F, Kalantar-Zadeh K, Sumida K, Kovesdy C
J Ren Nutr
. 2024 Mar;
34(6):500-508.
PMID: 38513825
Objective: Loss of muscle mass and sarcopenia are common in chronic kidney disease (CKD) and end-stage renal disease (ESRD), and sarcopenia can worsen insidiously in patients with advancing CKD. The...
17.
Sackeyfio A, Lopes R, Kovesdy C, Cases A, Mallett S, Ballew N, et al.
Clin Kidney J
. 2024 Jan;
17(1):sfad298.
PMID: 38250252
Background: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are oral alternatives to current standard-of-care treatments for anaemia in chronic kidney disease (CKD). We conducted network meta-analyses to indirectly compare clinical outcomes...
18.
Obi Y, Thomas F, Dashputre A, Goedecke P, Kovesdy C
Kidney Med
. 2024 Jan;
6(1):100757.
PMID: 38192434
Rationale & Objective: Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to...
19.
You A, Kalantar-Zadeh K, Brent G, Narasaki Y, Daza A, Sim J, et al.
Mayo Clin Proc
. 2024 Jan;
99(1):39-56.
PMID: 38176833
Objective: To examine the relationship between thyroid status and incident kidney dysfunction/chronic kidney disease (CKD) progression. Patients And Methods: We examined incident thyroid status, ascertained by serum thyrotropin (TSH) levels...
20.
Kahn S, Anderson C, Buse J, Selvin E, Angell S, Aroda V, et al.
Diabetes Care
. 2023 Dec;
47(1):4-6.
PMID: 38117988
No abstract available.